BioSpace News Archive

A University of Houston chemist is exploring the link between copper protein molecules in brain cells and their link to neurodegenerative diseases like Alzheimer’s.

Janssen Research and Development forged a multi-target discovery agreement with San Diego-based AlivaMab Discovery Services that will use the company’s proprietary antibody discovery platform.

Mologic Ltd announced that it has finished recruitment to a major clinical trial with University College London Hospitals (UCLH) to evaluate the Company’s point-of-care (POC) diagnostic test for the early detection of sepsis.

Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid.

Auris Medical Holding Ltd. announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen® from the U.S. Food and Drug Administration and from the European Medicines Agency.

Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication

Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., presented data from the Phase 1 clinical trial of AKCEA-TTR-LRx in a poster presentation at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia, Pennsylvania.

BioCardia announced that the independent Data Safety Monitoring Board has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019.